Session » Muscle Biology, Myositis and Myopathies Poster II

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1858

A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients

1:00PM-3:00PM: Abstract Number: 1879

Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies

1:00PM-3:00PM: Abstract Number: 1863

Aromatase Inhibitor Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model

1:00PM-3:00PM: Abstract Number: 1875

Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin

1:00PM-3:00PM: Abstract Number: 1881

Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals

1:00PM-3:00PM: Abstract Number: 1883

Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype

1:00PM-3:00PM: Abstract Number: 1874

Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1868

B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease

1:00PM-3:00PM: Abstract Number: 1870

Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody Positive Dermatomyositis

1:00PM-3:00PM: Abstract Number: 1887

Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1882

Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series

1:00PM-3:00PM: Abstract Number: 1876

Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)

1:00PM-3:00PM: Abstract Number: 1864

Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response

1:00PM-3:00PM: Abstract Number: 1885

Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients

1:00PM-3:00PM: Abstract Number: 1871

Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)

1:00PM-3:00PM: Abstract Number: 1878

Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis

1:00PM-3:00PM: Abstract Number: 1884

Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska

1:00PM-3:00PM: Abstract Number: 1857

Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic

1:00PM-3:00PM: Abstract Number: 1865

Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria

1:00PM-3:00PM: Abstract Number: 1862

Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial

1:00PM-3:00PM: Abstract Number: 1860

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis

1:00PM-3:00PM: Abstract Number: 1869

Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity

1:00PM-3:00PM: Abstract Number: 1877

Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies

1:00PM-3:00PM: Abstract Number: 1872

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study

1:00PM-3:00PM: Abstract Number: 1866

Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database

1:00PM-3:00PM: Abstract Number: 1861

Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones

1:00PM-3:00PM: Abstract Number: 1873

Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively

1:00PM-3:00PM: Abstract Number: 1886

Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up

1:00PM-3:00PM: Abstract Number: 1856

Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram

1:00PM-3:00PM: Abstract Number: 1859

Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody

1:00PM-3:00PM: Abstract Number: 1880

Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys

1:00PM-3:00PM: Abstract Number: 1867

YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].